PE20211814A1 - Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas - Google Patents
Composiciones y metodos de construcciones quimericas del virus del dengue en vacunasInfo
- Publication number
- PE20211814A1 PE20211814A1 PE2021000217A PE2021000217A PE20211814A1 PE 20211814 A1 PE20211814 A1 PE 20211814A1 PE 2021000217 A PE2021000217 A PE 2021000217A PE 2021000217 A PE2021000217 A PE 2021000217A PE 20211814 A1 PE20211814 A1 PE 20211814A1
- Authority
- PE
- Peru
- Prior art keywords
- dengue virus
- dengue
- den
- constructs
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 241000725619 Dengue virus Species 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 238000010276 construction Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000035772 mutation Effects 0.000 abstract 4
- 229930024421 Adenine Natural products 0.000 abstract 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 abstract 3
- 208000001490 Dengue Diseases 0.000 abstract 3
- 206010012310 Dengue fever Diseases 0.000 abstract 3
- 229960000643 adenine Drugs 0.000 abstract 3
- 208000025729 dengue disease Diseases 0.000 abstract 3
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 241000710815 Dengue virus 2 Species 0.000 abstract 2
- 241000710872 Dengue virus 3 Species 0.000 abstract 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 abstract 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 abstract 2
- 241000710827 Dengue virus 1 Species 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 229940104302 cytosine Drugs 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 229940113082 thymine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
- C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
- C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
- C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24141—Use of virus, viral particle or viral elements as a vector
- C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361800204P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/024603 WO2014150939A2 (en) | 2013-03-15 | 2014-03-12 | Compositions and methods for dengue virus chimeric constructs in vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211814A1 true PE20211814A1 (es) | 2021-09-14 |
Family
ID=50678274
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000217A PE20211814A1 (es) | 2013-03-15 | 2014-03-12 | Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas |
| PE2015001953A PE20160027A1 (es) | 2013-03-15 | 2014-03-12 | Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015001953A PE20160027A1 (es) | 2013-03-15 | 2014-03-12 | Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas |
Country Status (33)
| Country | Link |
|---|---|
| US (6) | US9783579B2 (https=) |
| EP (5) | EP4129330B1 (https=) |
| JP (2) | JP6818548B2 (https=) |
| KR (4) | KR102626270B1 (https=) |
| CN (5) | CN113637694B (https=) |
| AR (4) | AR095598A1 (https=) |
| AU (2) | AU2014235476B2 (https=) |
| CA (4) | CA3177574C (https=) |
| CR (1) | CR20150569A (https=) |
| DK (1) | DK4129330T5 (https=) |
| DO (1) | DOP2015000232A (https=) |
| EC (1) | ECSP23013715A (https=) |
| ES (2) | ES2933970T3 (https=) |
| FI (2) | FI3539565T3 (https=) |
| FR (1) | FR22C1064I2 (https=) |
| HR (1) | HRP20231581T1 (https=) |
| HU (2) | HUE061507T2 (https=) |
| LT (2) | LT4129330T (https=) |
| LU (1) | LUC00329I2 (https=) |
| MX (5) | MX374519B (https=) |
| MY (1) | MY187796A (https=) |
| NL (1) | NL301223I2 (https=) |
| NO (1) | NO2023026I1 (https=) |
| NZ (1) | NZ630869A (https=) |
| PE (2) | PE20211814A1 (https=) |
| PH (1) | PH12015502120B1 (https=) |
| PL (1) | PL3539565T3 (https=) |
| PT (1) | PT3539565T (https=) |
| SG (3) | SG10201913435TA (https=) |
| SI (1) | SI4129330T1 (https=) |
| TW (4) | TWI733646B (https=) |
| UY (1) | UY35489A (https=) |
| WO (1) | WO2014150939A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20231581T1 (hr) | 2013-03-15 | 2024-03-15 | Takeda Vaccines, Inc. | Pripravci i postupci za kimerne konstrukte virusa denga groznice u cjepivima |
| US10004795B2 (en) * | 2015-09-08 | 2018-06-26 | Fundacao Butantan | Process for preparing an attenuated tetravalent dengue vaccine |
| EP3382012A4 (en) * | 2015-11-27 | 2019-07-03 | KM Biologics Co., Ltd. | LIVING VIRUS WITH A BANK OF ATTENUATED TREES OF DENGUEVIRUS AND DENGUE VACCINE THEREFORE AS ANTIGENE |
| US11007261B2 (en) * | 2016-04-13 | 2021-05-18 | Takeda Vaccines, Inc. | Compositions and methods of vaccination against dengue virus in children and young adults |
| WO2020051334A1 (en) | 2018-09-05 | 2020-03-12 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| US11426461B2 (en) | 2018-09-05 | 2022-08-30 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis A |
| EP4110381A1 (en) | 2020-02-27 | 2023-01-04 | Takeda Vaccines, Inc. | Method for removing host cell dna from virus preparation |
| WO2021173597A1 (en) * | 2020-02-28 | 2021-09-02 | Merck Sharp & Dohme Corp. | Dengue serotype specific rt-pcr multiplex assay |
| EP3892737A1 (en) * | 2020-04-09 | 2021-10-13 | Takeda Vaccines, Inc. | Qualitative and quantitative determination of single virus haplotypes in complex samples |
| WO2023147337A2 (en) | 2022-01-25 | 2023-08-03 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
| WO2023158989A1 (en) | 2022-02-15 | 2023-08-24 | Takeda Vaccines, Inc. | Dengue vaccine batch mixing process |
| EP4519847A1 (en) | 2022-05-04 | 2025-03-12 | Takeda Vaccines, Inc. | Computer-based determination of flavivirus infectivity |
| CN116479167A (zh) * | 2022-08-30 | 2023-07-25 | 深圳大学 | 登革病毒的pcr检测方法 |
| EP4357464A1 (en) * | 2022-10-20 | 2024-04-24 | Takeda Vaccines, Inc. | A method for detecting the presence of a dengue virus serotype in a sample containing at least one dengue virus serotype |
| EP4375381B1 (en) | 2022-11-18 | 2026-02-25 | Takeda Vaccines, Inc. | A method for determining the proportion of a live, attenuated dengue virus having a nucleotide sequence comprising at least one attenuation locus in a formulation |
| CN120529951A (zh) | 2022-11-29 | 2025-08-22 | 武田疫苗股份有限公司 | 大规模黄病毒疫苗生产和制造 |
| WO2025122855A1 (en) | 2023-12-08 | 2025-06-12 | Takeda Vaccines, Inc. | A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells |
| CN119824145A (zh) * | 2025-03-03 | 2025-04-15 | 广州市疾病预防控制中心(广州市卫生检验中心、广州市食品安全风险监测与评估中心、广州医科大学公共卫生研究院) | 一种对登革病毒的逆转录产物进行扩增的pcr引物、pcr试剂盒以及检测登革病毒的方法 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5276941A (en) | 1975-12-23 | 1977-06-28 | Ito Masato | Method of conversing infrared rays |
| US4810092A (en) | 1986-02-21 | 1989-03-07 | Midac Corporation | Economical spectrometer unit having simplified structure |
| JPH0768267B2 (ja) | 1986-06-05 | 1995-07-26 | 財団法人阪大微生物病研究会 | フラビウイルス抗原 |
| JPH084508B2 (ja) | 1987-09-16 | 1996-01-24 | 国立予防衛生研究所長 | 組み換えワクチニアウイルス |
| JP2511494B2 (ja) | 1988-05-12 | 1996-06-26 | 善治 松浦 | 日本脳炎ウイルス表面抗原蛋白質の製造法 |
| US6184024B1 (en) | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
| IL91304A0 (en) | 1988-08-20 | 1990-03-19 | Us Health | Recombinant vaccinia virus for prevention of disease caused by flavivirus |
| US5514375A (en) | 1990-08-15 | 1996-05-07 | Virogenetics Corporation | Flavivirus recombinant poxvirus vaccine |
| MY109299A (en) | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
| US5494671A (en) | 1990-08-27 | 1996-02-27 | The United States Of America As Represented By The Department Of Health And Human Services | C-terminally truncated dengue and Japanese encephalitis virus envelope proteins |
| DE69231570T2 (de) | 1991-09-19 | 2001-06-21 | Us Of America Represented By D | Chimäre und/oder wachstumgehemmte Flaviviren |
| JPH05276941A (ja) | 1992-02-28 | 1993-10-26 | Nippon Zeon Co Ltd | フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法 |
| WO1996037221A1 (en) | 1995-05-24 | 1996-11-28 | Hawaii Biotechnology Group, Inc. | Subunit vaccine against flavivirus infection |
| AU6093296A (en) * | 1995-06-07 | 1996-12-30 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Infectious dengue 2 virus pdk-53 as quadravalent vaccine |
| HU228705B1 (en) | 1997-02-28 | 2013-05-28 | Univ St Louis | Chimeric flavivirus vaccines |
| ATE314476T1 (de) | 1997-10-08 | 2006-01-15 | Us Gov Health & Human Serv | Chimärer impfstoff gegen das zeckenenzephalitis virus |
| DE29810020U1 (de) | 1998-06-04 | 1998-09-24 | Siemens AG, 80333 München | Kunststoffbehälter zur Tieftemperaturlagerung von biologischen Materialien |
| US7417136B1 (en) | 1998-06-04 | 2008-08-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
| WO2001039802A1 (en) * | 1999-12-01 | 2001-06-07 | Oravax, Inc. | Chimeric flavivirus vaccines |
| EP3000477A1 (en) * | 2000-02-16 | 2016-03-30 | The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, | Avirulent, immunogenic flavivirus chimeras |
| ATE412738T1 (de) * | 2000-05-30 | 2008-11-15 | Univ Mahidol | Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen |
| WO2002072036A2 (en) | 2001-03-12 | 2002-09-19 | Yale University | Compositions and methods comprising west nile virus polypeptides |
| BRPI0613287A2 (pt) | 2005-06-17 | 2010-12-28 | Sanofi Pasteur | cepa do vìrus da dengue-2 vivo atenuada, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada codificadas pela seq id n .1 ou fragmentos desta e fragmento da poliproteìna |
| CN101238144B (zh) * | 2005-06-17 | 2012-09-05 | 赛诺菲巴斯德有限公司 | 登革血清型1减毒株 |
| KR20070017759A (ko) | 2005-08-08 | 2007-02-13 | 삼성전자주식회사 | 초해상 정보 저장 매체, 기록/재생 장치 및 기록/재생 방법 |
| US20080193477A1 (en) * | 2005-08-10 | 2008-08-14 | Acambis Inc. | Vaccination Against Dengue Virus Infection |
| US7968102B2 (en) * | 2006-01-13 | 2011-06-28 | Sanofi Pasteur S.A. | Dengue chimeric viruses |
| DK2589602T3 (en) * | 2006-08-15 | 2016-07-25 | The Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of | Development of dengue virus vaccine components |
| DK2178903T3 (da) | 2007-07-13 | 2012-06-18 | Florida Gulf Coast University | Optimeret denguevirus-adgangsinhiberede peptid (DN81) |
| US8715689B2 (en) * | 2008-04-30 | 2014-05-06 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Chimeric west nile/dengue viruses |
| SG157244A1 (en) | 2008-05-15 | 2009-12-29 | Mp Biomedicals Asia Pacific Pte Ltd | Point of care test for the detection of exposure or immunity to dengue virus |
| WO2010085358A2 (en) * | 2009-01-23 | 2010-07-29 | The Board Of Regents Of The University Of Texas System | Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof |
| US8968996B2 (en) | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
| NZ597000A (en) | 2009-06-01 | 2014-07-25 | Takeda Vaccines Inc | Compositions and methods for administration of vaccines against dengue virus |
| CN101560520A (zh) * | 2009-06-04 | 2009-10-21 | 中国疾病预防控制中心病毒病预防控制所 | 乙脑/登革嵌合病毒及其应用 |
| BRPI0904020B8 (pt) * | 2009-10-01 | 2021-05-25 | Fundacao Oswaldo Cruz | composição vacinal contra o vírus da dengue, e, kit |
| EP2353609A1 (en) | 2010-02-04 | 2011-08-10 | Sanofi Pasteur | Immunization compositions and methods |
| NZ630831A (en) | 2012-06-10 | 2019-02-22 | Takeda Vaccines Inc | Compositions and methods for administration of vaccines against dengue virus |
| MX381497B (es) | 2012-07-24 | 2025-03-12 | Sanofi Pasteur | Composiciones vacuna. |
| KR20150036593A (ko) | 2012-07-24 | 2015-04-07 | 사노피 파스퇴르 | 뎅기열 바이러스 감염 예방용 백신 조성물 |
| TW201920677A (zh) | 2012-11-08 | 2019-06-01 | 美商武田疫苗股份有限公司 | 登革熱病毒血清型４型之建構物的組成物、方法及用途 |
| JP2016504315A (ja) * | 2012-12-14 | 2016-02-12 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | 三価デングウイルス製剤に関する組成物、投与方法および使用 |
| HRP20231581T1 (hr) | 2013-03-15 | 2024-03-15 | Takeda Vaccines, Inc. | Pripravci i postupci za kimerne konstrukte virusa denga groznice u cjepivima |
| TWI852899B (zh) | 2014-09-02 | 2024-08-21 | 法商賽諾菲巴斯德公司 | 疫苗組合物 |
| WO2017005654A1 (en) | 2015-07-03 | 2017-01-12 | Sanofi Pasteur | Concomitant dengue, diphtheria, tetanus, whooping cough (pertussis), polio, and haemophilus influenzae type b vaccination. |
| BR112017028212A2 (pt) | 2015-07-03 | 2018-09-11 | Sanofi Pasteur | vacinação concomitante contra dengue e febre amarela |
| US10004795B2 (en) | 2015-09-08 | 2018-06-26 | Fundacao Butantan | Process for preparing an attenuated tetravalent dengue vaccine |
| US11007261B2 (en) | 2016-04-13 | 2021-05-18 | Takeda Vaccines, Inc. | Compositions and methods of vaccination against dengue virus in children and young adults |
| SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| CN111655844B (zh) | 2017-10-16 | 2024-05-24 | 印度血清研究所私人有限公司 | 包含特别是减毒活重组黄病毒的稳定的疫苗组合物及其制备方法 |
| US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| WO2020051334A1 (en) | 2018-09-05 | 2020-03-12 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| EP3892737A1 (en) | 2020-04-09 | 2021-10-13 | Takeda Vaccines, Inc. | Qualitative and quantitative determination of single virus haplotypes in complex samples |
-
2014
- 2014-03-12 HR HRP20231581TT patent/HRP20231581T1/hr unknown
- 2014-03-12 KR KR1020227013084A patent/KR102626270B1/ko active Active
- 2014-03-12 ES ES20154012T patent/ES2933970T3/es active Active
- 2014-03-12 CN CN202110718703.8A patent/CN113637694B/zh active Active
- 2014-03-12 PT PT191684752T patent/PT3539565T/pt unknown
- 2014-03-12 PH PH1/2015/502120A patent/PH12015502120B1/en unknown
- 2014-03-12 CA CA3177574A patent/CA3177574C/en active Active
- 2014-03-12 SI SI201432055T patent/SI4129330T1/sl unknown
- 2014-03-12 DK DK22182269.5T patent/DK4129330T5/da active
- 2014-03-12 CA CA2903231A patent/CA2903231C/en active Active
- 2014-03-12 LT LTEP22182269.5T patent/LT4129330T/lt unknown
- 2014-03-12 CN CN202010617988.1A patent/CN111778263B/zh active Active
- 2014-03-12 KR KR1020257006481A patent/KR20250033325A/ko active Pending
- 2014-03-12 CA CA3177572A patent/CA3177572C/en active Active
- 2014-03-12 CA CA3166063A patent/CA3166063A1/en active Pending
- 2014-03-12 ES ES22182269T patent/ES2965652T3/es active Active
- 2014-03-12 HU HUE19168475A patent/HUE061507T2/hu unknown
- 2014-03-12 CN CN202110723336.0A patent/CN113637086B/zh active Active
- 2014-03-12 CN CN201480028001.5A patent/CN105451763B/zh active Active
- 2014-03-12 MY MYPI2015002317A patent/MY187796A/en unknown
- 2014-03-12 AU AU2014235476A patent/AU2014235476B2/en active Active
- 2014-03-12 NZ NZ630869A patent/NZ630869A/en unknown
- 2014-03-12 EP EP22182269.5A patent/EP4129330B1/en active Active
- 2014-03-12 PE PE2021000217A patent/PE20211814A1/es unknown
- 2014-03-12 MX MX2015012893A patent/MX374519B/es active IP Right Grant
- 2014-03-12 EP EP14722014.9A patent/EP2968516B1/en active Active
- 2014-03-12 KR KR1020157029897A patent/KR102389908B1/ko active Active
- 2014-03-12 SG SG10201913435TA patent/SG10201913435TA/en unknown
- 2014-03-12 WO PCT/US2014/024603 patent/WO2014150939A2/en not_active Ceased
- 2014-03-12 EP EP19168475.2A patent/EP3539565B1/en active Active
- 2014-03-12 PL PL19168475.2T patent/PL3539565T3/pl unknown
- 2014-03-12 JP JP2016501585A patent/JP6818548B2/ja active Active
- 2014-03-12 CN CN202110718694.2A patent/CN113637693B/zh active Active
- 2014-03-12 SG SG11201507460PA patent/SG11201507460PA/en unknown
- 2014-03-12 EP EP22204593.2A patent/EP4183411A1/en active Pending
- 2014-03-12 KR KR1020247001384A patent/KR102775714B1/ko active Active
- 2014-03-12 PE PE2015001953A patent/PE20160027A1/es unknown
- 2014-03-12 EP EP20154012.7A patent/EP3689374B1/en active Active
- 2014-03-12 SG SG10201913387XA patent/SG10201913387XA/en unknown
- 2014-03-12 FI FIEP19168475.2T patent/FI3539565T3/fi active
- 2014-03-13 US US14/209,808 patent/US9783579B2/en active Active
- 2014-03-14 TW TW103109624A patent/TWI733646B/zh active
- 2014-03-14 TW TW110111747A patent/TWI894248B/zh active
- 2014-03-14 TW TW114128176A patent/TW202545972A/zh unknown
- 2014-03-14 TW TW108114540A patent/TWI726312B/zh active
- 2014-03-17 AR ARP140101223A patent/AR095598A1/es active IP Right Grant
- 2014-03-17 UY UY35489A patent/UY35489A/es active IP Right Grant
-
2015
- 2015-09-11 DO DO2015000232A patent/DOP2015000232A/es unknown
- 2015-09-14 MX MX2023000353A patent/MX2023000353A/es unknown
- 2015-09-14 MX MX2023000354A patent/MX2023000354A/es unknown
- 2015-09-14 MX MX2023000349A patent/MX2023000349A/es unknown
- 2015-09-14 MX MX2019003602A patent/MX2019003602A/es unknown
- 2015-10-15 CR CR20150569A patent/CR20150569A/es unknown
-
2017
- 2017-04-20 US US15/492,981 patent/US10449231B2/en active Active
-
2019
- 2019-06-05 JP JP2019105307A patent/JP7050031B2/ja active Active
- 2019-08-16 AU AU2019216724A patent/AU2019216724C1/en active Active
- 2019-09-05 US US16/561,755 patent/US20200061151A1/en not_active Abandoned
-
2021
- 2021-09-17 US US17/478,537 patent/US12186363B2/en active Active
- 2021-10-06 AR ARP210102772A patent/AR123702A2/es unknown
-
2022
- 2022-12-12 US US18/064,775 patent/US11931399B2/en active Active
- 2022-12-16 FR FR22C1064C patent/FR22C1064I2/fr active Active
-
2023
- 2023-02-24 EC ECSENADI202313715A patent/ECSP23013715A/es unknown
- 2023-03-08 NL NL301223C patent/NL301223I2/nl unknown
- 2023-06-20 HU HUS2300022C patent/HUS2300022I1/hu unknown
- 2023-06-27 FI FIC20230021C patent/FIC20230021I1/fi unknown
- 2023-07-04 NO NO2023026C patent/NO2023026I1/no unknown
-
2024
- 2024-02-27 LU LU00329C patent/LUC00329I2/fr unknown
- 2024-02-28 AR ARP240100498A patent/AR132009A2/es unknown
- 2024-03-05 LT LTPA2024503C patent/LTPA2024503I1/lt unknown
- 2024-07-10 US US18/768,774 patent/US20250018006A1/en active Pending
- 2024-07-16 AR ARP240101841A patent/AR133264A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211814A1 (es) | Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas | |
| AR093421A1 (es) | Composiciones, metodos y usos de construcciones de virus del dengue de serotipo-4 | |
| BR112018071087A2 (pt) | composições e métodos de vacinação contra o vírus da dengue em crianças e adultos jovens | |
| CL2017001769A1 (es) | Compuestos derivados de nucleosidos, nucleotidos y análogos de los mismos; composición farmacéutica que los comprende; útiles en el tratamiento de la hepatitis c (divisional de la solicitud 1699-2015). | |
| MX2019012360A (es) | Composiciones y metodos mejorados de celulas t. | |
| PE20160217A1 (es) | Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales | |
| CL2011001082A1 (es) | Compuestos derivados de amino-tetrahidropiranos sustituidos con heterociclos, composicion farmaceutica; y uso en el tratamiento de una afeccion seleccionada de resistencia a la insulina, hiperglicemia y diabetes de tipo 2. | |
| BR112015001313A2 (pt) | composições de vacina | |
| CR11327A (es) | Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas | |
| ATE510811T1 (de) | Azeotrop-ähnliche zusammensetzung aus 2-chlor-1,1,1,2-tetrafluorpropan (hcfc-244bb) und wasserstofffluorid (hf) | |
| AR096863A1 (es) | Composiciones de caucho natural mejoradas | |
| ES2387141T8 (es) | Composición que comprende la poliproteína NS3/NS4 y el polipéptido NS5b del VHC, vectores de expresión que incluyen las secuencias nucleicas correspondientes y su utilización terapéutica | |
| JP2016504315A5 (https=) | ||
| PE20181087A1 (es) | SISTEMA VECTOR DE ADENOVIRUS AVIAR 9 (FAdV-9) Y METODOS ASOCIADOS | |
| CL2011002619A1 (es) | Compuestos derivados de arilsulfonamidas, moduladores de la actividad del receptor ccr3; composición farmacéutica que los comprende; utiles en el traramiento de una enfermedad inflamatoria tal como asma, rinitis alergica, dermatitis atopica, epoc entre otras. | |
| CL2011001034A1 (es) | Compuestos derivados de pirrolidina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como endometriosis, fibroides uterinos, menorragia, entre otras. | |
| BR112016029201B8 (pt) | Quimera de ácido nucleico, composição imunogênica, uso de um ou mais vírus inativados compreendendo a quimera de ácido nucleico e método para inativar um vírus | |
| BR112021007105A2 (pt) | Zika vírus recombinante vivo atenuado, zika vírus recombinante, partícula de zika vírus recombinante ou ácido nucleico de zika vírus recombinante, ácido nucleico recombinante, isolado ou substancialmente purificado, vetor, célula ou isolado, vacina, preparação farmacêutica, composição imunogênica, uso, e, métodos para tratar um sujeito com uma infecção viral por zika natural, reduzir a gravidade de uma infecção viral por zika natural em um sujeito ou prevenir um sujeito de contrair uma infecção viral por zika naturalmente, para gerar uma vacina de zika vírus vivo atenuado, zika vírus recombinante, partícula de zika vírus recombinante ou ácido nucleico de zika vírus recombinante e para preparar uma vacina compreendendo zika vírus recombinante vivo atenuado | |
| TH170668A (th) | องค์ประกอบ และวิธีการสำหรับชุดโครงสร้างไคมีริกไวรัสเด็งกีในวัคซีน | |
| Ghosal et al. | Formulation and characterization of both hydrophilic and hydrophobic HPMC based hydrogels containing diclofenac potassium | |
| MX350236B (es) | Composiciones de peptidos para el tratamiento y diagnostico de la fiebre por virus del dengue. | |
| CO6321231A2 (es) | Imidazolil-bifenil-imidazoles como inhibidores del virus de la hepatitis c |